Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Obecabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Obecabtagene autoleucel overview
Obecabtagene autoleucel (Aucatzyl) is a genetically modified autologous T cell immunotherapy. It is formulated as suspension for intravenous route of administration. Aucatzyl is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Obecabtagene autoleucel is under development for the treatment of relapsed or refractory CD19 positive acute lymphoblastic leukemia in adults and pediatrics, diffuse large B cell lymphoma, systemic lupus erythematosus, B-cell acute lymphoblastic leukaemia, chronic lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, primary CNS lymphoma, Burkitt lymphoma and primary mediastinal large B-cell lymphoma. It is administered as an intravenous infusion. The therapeutic candidate constitutes patient's own T cells transduced with lentiviral vector that have been genetically modified to express CD19CAT-41BBZ targeting CD19. It was under development for the treatment of marginal zone lymphoma.
Autolus Therapeutics overview
Autolus Therapeutics (Autolus) is a biopharmaceutical company that specializes in the development of advanced autologous T cell therapies. It focuses on creating treatments for patients with cancer and autoimmune diseases. The company’s lead therapeutic candidate is obe-cel, a chimeric antigen receptor (CAR) T cell therapy designed to recognise and eradicate cancer cells. Autolus’ products are primarily used in the healthcare industry, specifically in the treatment of hematological malignancies and solid tumors. The company’s target market includes patients suffering from cancer and autoimmune diseases, with a particular focus on adult acute lymphoblastic leukemia (ALL), B-cell Non-hodgkin lymphoma (B-NHL), and pediatric ALL. Autolus Therapeutics is headquartered in London, England, the UK.
For a complete picture of Obecabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
